OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Pharmacological profile of once-weekly injectable semaglutide for chronic weight management
David C.W. Lau, Rachel L. Batterham, Carel W. le Roux
Expert Review of Clinical Pharmacology (2022) Vol. 15, Iss. 3, pp. 251-268
Open Access | Times Cited: 12

Showing 12 citing articles:

A phase 2 randomised controlled trial of mazdutide in Chinese overweight adults or adults with obesity
Linong Ji, Hongwei� Jiang, Zhi-Feng Cheng, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 29

NK2R control of energy expenditure and feeding to treat metabolic diseases
Frederike Sass, Tao Ma, Jeppe H. Ekberg, et al.
Nature (2024) Vol. 635, Iss. 8040, pp. 987-1000
Open Access | Times Cited: 9

A systematic review of the safety of tirzepatide-a new dual GLP1 and GIP agonist - is its safety profile acceptable?
Zhuqing Meng, Min Yang, Haibo Wen, et al.
Frontiers in Endocrinology (2023) Vol. 14
Open Access | Times Cited: 9

The potential role of GLP-1 receptor agonist targeting in fertility-sparing treatment in obese patients with endometrial malignant pathology: a call for research
Caroline J. Violette, Ravi Agarwal, Rachel S. Mandelbaum, et al.
Expert Review of Anticancer Therapy (2023) Vol. 23, Iss. 4, pp. 385-395
Closed Access | Times Cited: 7

USO DO MEDICAMENTO SEMAGLUTIDA COMO ALIADO NO TRATAMENTO DA OBESIDADE
Thamires Pires Weber, Isabella Elias Bosco, Letícia Martins Barroso, et al.
RECIMA21 - Revista Científica Multidisciplinar - ISSN 2675-6218 (2023) Vol. 4, Iss. 2, pp. e422731-e422731
Open Access | Times Cited: 4

EXPLORING THE UNINTENDED CONSEQUENCES OF MISUSE OF WEGOVY AND OZEMPIC IN WEIGHT MANAGEMENT: A COMPREHENSIVE REVIEW
SARTHAK A. KUTE, Madhura S. Chothave, PRAJAKTA B. ROTE, et al.
International Journal of Pharmacy and Pharmaceutical Sciences (2024), pp. 10-13
Open Access | Times Cited: 1

Exploring the antioxidant properties of semaglutide: A comprehensive review
Habib Yaribeygi, Mina Maleki, Behina Forouzanmehr, et al.
Journal of Diabetes and its Complications (2024) Vol. 38, Iss. 12, pp. 108906-108906
Closed Access | Times Cited: 1

Gastrointestinal adverse events of semaglutide in patients with overweight or obesity
Muhammad Ali Tariq, Hamza Amin, Qazi Shurjeel, et al.
European Journal of Internal Medicine (2022) Vol. 106, pp. 138-139
Closed Access | Times Cited: 3

Application of liquid chromatography-mass spectrometry for the determination of semaglutide in human serum in clinical pharmacokinetic studies
P. K. Karnakova, Е. S. Vetrova, P. A. Karpova, et al.
Meditsinskiy sovet = Medical Council (2024), Iss. 16, pp. 246-255
Open Access

The Therapeutic Aspects of Obesity
T. М. Bentsa
Family medicine European practices (2023), Iss. 3, pp. 88-92
Open Access | Times Cited: 1

Semaglutide is precipitating a revolution in obesity care
Khaled Alabduljabbar, Carel W. le Roux, Royce P Vincent
Translational Metabolic Syndrome Research (2022) Vol. 5, pp. 24-26
Open Access | Times Cited: 1

Page 1

Scroll to top